Biopharmaceutical company developing treatment for schizophrenia, bipolar depression, and other neuropsychiatric diseases—LB Pharmaceuticals (LBRX)—raised $285 million in its U.S. IPO, making it the first sizable biotech IPO since February 2025.
The company issued 19 million shares at $15 each, in line